Mandate

Vinge advises Expedition Growth Capital in connection with investment in Xensam  

Expedition Growth Capital has today announced a $40 million growth investment in the Swedish SaaS company Xensam. Vinge acted as Expedition Growth Capital’s legal advisor in connection with the investment.

Xensam is a provider of an AI-powered Software Assessment Management (SAM) platform. The platform enables its customers to understand how users interact with applications, whether SaaS or on-premise, across the entire digital infrastructure to provide a comprehensive organisational overview across hybrid environments.

Expedition Growth Capital is a London-based growth fund focused on investing in fast-growing companies.

Vinge’s team consisted of Karl Klackenberg, Clara Sohlberg and Johan Gavelin (M&A), Rebecka Målquist (IP), Olivia Onwuta (Employment) and Anna Ekdahl Roos (Transaction Support).

 

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025